John is currently a Senior Director and Global Development Lead for NGS Technologies at Qiagen Corporation. He has published 25 papers, sits on several scientific advisory boards and is an inventor on numerous issued patents and patent applications
While next-generation sequencing has proven to be a very useful tool in basic research, two major hurdles remain for its broad adoption in the clinical research setting: lack of seamless workflow for routine clinical research use and truly relevant content to guide clinical research activities.
This webinar will discuss QIAGEN's approach to address these two issues. Our speaker, Dr. John Leamon, will share his experience developing and launching the industry’s first complete NGS workflow: The GeneReader System. The GeneReader offers a fully integrated solution, addressing all steps of the workflow from DNA extraction to bioinformatics analysis and interpretation. It is engineered specifically for any laboratory as a powerful tool for clinical cancer research, including those with limited resources or lacking highly specialized expertise. To this end, the QIAGEN proprietary Knowledge Base was used to design a tumor panel to identify aberrations of value for clinical research. The GeneReader NGS System was then used to deliver clinical research insights in a laboratory setting. Testing was conducted with a set of colorectal cancer samples, and results confirmed with alternative testing platforms.
The QIAGEN GeneReader NGS System is a fully integrated sequencing workflow, engineered specifically for clinical research purposes. This turnkey solution is purpose-built, focusing on the assays that matter most.